About: Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
Creator	Soler, María D'marco, Luis Fernandez-Fernandez, Beatriz Jacobs-Cachá, Conxita Kanbay, Mehmet Luis-Lima, Sergio Ortiz, Alberto Porrini, Esteban Sarafidis, Pantelis Luis Górriz, Jose
source	Medline; PMC
abstract	Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboembolic complications and replacing or supporting organ function. However, despite organ support, mortality is currently 65% for those receiving advanced respiratory support and 78% for those requiring renal replacement therapies. Thus, efforts should be made to provide adjuvant organ protection therapy. This may imply novel therapies in clinical development (e.g., the Fas ligand trap asunercept), but uptake of repurposed drugs already in clinical use may be faster. In this regard, sodium glucose co-transporter-2 (SGLT2) inhibitors were recently shown to protect the heart and kidney both within and outside of a diabetic milieu context. Further, preclinical data support a beneficial effect for the lung. We now discuss the potential benefits and risks of SGLT2 inhibitors in COVID-19 and an ongoing clinical trial testing the impact of dapagliflozin on outcomes in COVID-19 patients with respiratory failure.
has issue date	2020-06-28(xsd:dateTime)
bibo:doi	10.3390/jcm9072030
bibo:pmid	32605278
has license	cc-by
sha1sum (hex)	67abf66f8381a6d3522e2e5ba156a3ef3f62e576
schema:url	https://doi.org/10.3390/jcm9072030
resource representing a document's title	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
has PubMed Central identifier	PMC7409231
has PubMed identifier	32605278
schema:publication	J Clin Med
resource representing a document's body	covid:67abf66f8381a6d3522e2e5ba156a3ef3f62e576#body_text
is schema:about of	named entity 'preventing' named entity 'function' named entity 'This' named entity 'mortality' named entity 'severe' named entity 'inhibitors' named entity 'clinical development' named entity 'Inhibitors' named entity 'SGLT2' named entity 'Exploring' named entity 'PATIENTS' named entity 'ADJUVANT' named entity 'FASTER' named entity 'SPREAD' named entity 'beneficial' named entity 'limiting' named entity 'thromboembolic' named entity 'regard' named entity 'inflammatory' named entity 'sodium glucose co-transporter-2' named entity 'preclinical' named entity 'support' named entity 'COVID-19' named entity 'patients' named entity 'lung' named entity 'lung' named entity 'organ' named entity 'COVID' named entity 'COVID' named entity 'organ' named entity 'diabetic' named entity 'Therapeutic approaches' named entity 'SGLT2' named entity 'COVID-19' named entity 'COVID-19' named entity 'Russia' named entity 'COVID-19' named entity 'COVID-19' named entity 'patient-years' named entity 'SGLT2' named entity 'hydroxylated' named entity 'renin-angiotensin' named entity 'distal' named entity 'human lung' named entity 'oral hypoglycemic agents' named entity 'SARS-CoV' named entity 'insulin' named entity 'COVID-19' named entity 'COVID-19' named entity 'recombinant' named entity 'hypertension' named entity 'SARS-CoV-2' named entity 'type 2' named entity 'arteriole' named entity 'acute respiratory failure' named entity 'renal proximal tubules' named entity 'cardiovascular disease' named entity 'all-cause mortality' named entity 'weight loss' named entity 'albuminuria' named entity 'TMPRSS2' named entity 'lopinavir' named entity 'SGLT2 inhibitors' named entity 'coronaviruses' named entity 'CD147' named entity 'kidney' named entity 'virus entry' named entity 'fecal-oral transmission' named entity 'CKD' named entity 'serine protease' named entity 'nafamostat' named entity 'metabolic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software